Percutaneous Fine-Needle 5% Ethanol-Cisplatin Intratumoral Injection Combined with Second-Line Chemotherapy Improves On the Standard of Care in Patients with Platinum-Pretreated Stage IV Non–Small Cell Lung Cancer  by Niu, Qi et al.
www.transonc.com
Trans la t iona l Onco logy Volume 7 Number 2 April 2014 pp. 303–308 303Percutaneous Fine-Needle 5%
Ethanol-Cisplatin Intratumoral
Injection Combined with
Second-Line Chemotherapy
Improves On the Standard of
Care in Patients with Platinum-
Pretreated Stage IV Non–Small
Cell Lung Cancer1Qi Niu*, Wei Wang*, Qian Li†, Yong Li*,
Douglas M. Ruden‡ and Baoming He§
*Department of Medical Oncology, No. 309 People’s
Liberation Army Hospital, Beijing, People's Republic of
China; †Department of Internal Medicine, Beijing Language
and Culture University Hospital, Beijing, People's Republic of
China; ‡Department of Obstetrics and Gynecology, Institute
of Environmental Health Sciences, CS Mott Center for
Human Health and Development, Wayne State University,
Detroit, MI, USA; §Department of Radiology, No. 309
People’s Liberation Army Hospital, Beijing, People's
Republic of ChinaAbstract
BACKGROUND: Efficacy of second-line chemotherapy in platinum-pretreated non–small cell lung cancer (NSCLC)
is poor. This study investigated efficacy of computed tomography–guided percutaneous fine-needle 5% ethanol-
cisplatin intratumoral injection (CT-PFNECII) combined with second-line chemotherapy in patients with platinum-
pretreated stage IV NSCLC. PATIENTS: Between October 2011 and July 2013, 34 eligible patients were randomly
assigned to receive either CT-PFNECII combined with second-line chemotherapy (combination group, n = 17) or
second-line chemotherapy alone (chemotherapy group, n = 17). The primary end points were the proportions of
patients who achieved an overall response rate (ORR) and disease control rate (DCR). Secondary end points were
median survival and progression-free survival (PFS). RESULTS: The ORR and DCR in the combination group were
significantly higher than in the chemotherapy group (23.53% vs 11.76% for ORR, P b .01; and 58.82% vs 35.29%
for DCR, P b .01). Compared with patients in the chemotherapy group, patients in the combination group had
significantly longer PFS (5.4 months vs 3.0 months, P b .01) and median survival (9.5 months vs 5.3 months, P b .01).
CONCLUSIONS: CT-PFNECII combined with second-line chemotherapy provided a higher response rate and
improved survival than second-line chemotherapy for patients with platinum-pretreated stage IV NSCLC.
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Lung cancer is the most common cancer in the world, and non–
small cell lung cancer (NSCLC) accounts for approximately 80% of
all cases of lung cancer. Platinum-based chemotherapy is the
standard first-line care for NSCLC [1,2]. However, platinum
resistance and tumor recurrence, which are believed to be mediated
by cancer stem-like cells (CSCs) or side-population cells, invariably
develop [3–5]. Currently, second-line chemotherapy is the standard
of care for platinum-pretreated NSCLC even though its efficiency is
poor [1,2,5].
Docetaxel and pemetrexed are currently the standard second-line
chemotherapy agents for NSCLC. Treatment with pemetrexed
generally results in clinically equivalent efficacy outcomes with
docetaxel in the second-line treatment of patients with advancedNSCLC [1]. However, pemetrexed and docetaxel only produced
overall response rates (ORRs) of 9.1% and 8.8% with a median
survival time of 8.3 and 7.9 months, respectively, in platinum-
pretreated NSCLC [1].
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inhibitors (TKIs) erlotinib and gefitinib have also been used as
standard second-line agents in treating NSCLC. Sensitivity to EGFR
TKIs is dependent on the activation of the EGFR pathway or the
presence of EGFR-interacting proteins [5]. Studies showed that no
significant differences in efficacy were noted between patients treated
with TKIs and those treated with docetaxel or pemetrexed in
platinum-pretreated NSCLC [5–7].
Therapeutic inhibition of EGFR with TKIs has resulted in favorable
response rates only in 11.14% to 15.25% of platinum-pretreated
NSCLC, mostly because the EGFR mutation or gene amplification rate
is only 16.6% in NSCLC [5,6]. In addition, median survival of 7.6
months for gefitinib in platinum-pretreated NSCLC and 5.3 months for
erlotinib in platinum-resistant NSCLC indicate the desperate need for
novel approaches to treat the patient population [5,7–9].
We previously found that 5% ethanol-cisplatin injected intratu-
morally could eradicate cisplatin-resistant lung tumors and extend
survival by improved killing of lung CSCs in mice [10]. We believe
that 5% ethanol improves the efficacy of CSC killing by inhibiting
breast cancer resistance protein (BRCP/ABCG2) drug transporter
function and by improving the penetration of cisplatin into the tumor
cells [10]. On the basis of our model organism studies, it is possible
that computed tomography (CT)–guided percutaneous fine-needle
5% ethanol-cisplatin intratumoral injection (CT-PFNECII) might
also regress platinum-pretreated or even platinum-resistant tumors in
patients with NSCLC by killing chemoresistant cancer stem cells and
cancer cells. Furthermore, it is possible that the residual unkilled but
damaged tumor cells after 5% ethanol-cisplatin treatment might be
more fragile and sensitive to systemic second-line chemotherapy
agents. Thus, combination of CT-PFNECII with systemic second-
line chemotherapy might provide a new way to improve survival of
this patient population.
This study is aimed to investigate the efficacy and safety of CT-
PFNECII combined with second-line chemotherapy in patients with
platinum-pretreated stage IV NSCLC.
Patients and Methods
Patients
The study protocol was approved by the Institutional Review
Boards of the No. 309 People’s Liberation Army Hospital in Beijing,
and the study was performed in accordance with the ethical standards
laid down in the 1964 Declaration of Helsinki. Adult patients with
histologically documented NSCLC who received ≥1 platinum-based
chemotherapy regimen, with an Eastern Cooperative Oncology
Group (ECOG) performance status of 0 to 2, were potentially eligible
for this study. Patients were excluded if they had a life expectancy of
less than 1 month or had an indication for liver, renal, or heart failure.
Thirty-four eligible patients were enrolled in this study and asked for
written informed consent. Information collected at baseline included
sex, age, ECOG performance status, tumor size, histology, disease
stage, lung tumor–related chest pain or dyspnea, time since last
chemotherapy (interval from last chemotherapy to inclusion), times
of CT-PFNECII, and platinum resistance. Protocol design, data
collection, and analysis were solely the responsibility of the authors.
Study Design
Eligible patients were randomly assigned to receive either CT-
PFNECII combined with second-line chemotherapy (standardpemetrexed or docetaxel dosing schedule) (combination group, n =
17) or second-line chemotherapy (standard pemetrexed or docetaxel
dosing schedule) alone (chemotherapy group, n = 17).
If a patient received prior taxane treatment, such as docetaxel or
paclitaxel, pemetrexed was given as second-line chemotherapy.
Otherwise, docetaxel was given as second-line chemotherapy.
Ethanol-cisplatin (5%) was freshly prepared with 10 mg (2 ml) of
cisplatin (Qilu Pharmaceutical Co, Ltd, Shandong, China) dissolved into
an ethanol solution of 20 to 30ml with the final ethanol concentration of
5% (vol/vol). Next, the freshly prepared 20 to 30 ml of 5% ethanol-
cisplatin solution was percutaneously injected into the lung tumor
individually with a 22-gauge fine needle (Gallini Medical Devices, Via
Frattini, Italy) under CT (GE Healthcare, Waukesha, WI) guidance,
once a week. This procedure was performed weekly for two consecutive
weeks, and a third week with no treatment completed one cycle. Single
chemotherapy agent pemetrexed (Alimta; Eli Lilly and Company,
Indianapolis, IN) (500 mg/m2 as a 10-minute IV infusion on day 1 of a
21-day cycle) or docetaxel (Taxotere; Aventis Pharmaceuticals, Bridge-
water, NJ) (75 mg/m2 as a 1-hour IV infusion on day 1 of a 21-day
cycle) was administered IV 1 day after CT-PFNECII every 3 weeks as a
cycle. Each patient in the combination group received one to two cycles of
CT-PFNECII and four cycles of pemetrexed/docetaxel, and each patient
in the chemotherapy group received four cycles of pemetrexed/docetaxel.
Patients on the pemetrexed arm were instructed to take folic acid (350-
1000 μg) orally daily beginning approximately 1 to 2 weeks before the first
dose of pemetrexed and continuing daily until 3 weeks after the last dose of
pemetrexed. A 1000-μg vitamin B12 injection was administered
intramuscularly 1 week before the first dose of pemetrexed and was
repeated approximately every 9 weeks until after discontinuation. Patients
on the pemetrexed arm were instructed to take dexamethasone (Guizhou
Guangzheng Pharmaceuticals, Guizhou, China) (4 mg orally twice daily
the day before, the day of, and the day after pemetrexed) as a prophylactic
measure against skin rash. Patients on the docetaxel arm were instructed to
take dexamethasone (8mg orally twice daily the day before, the day of, and
the day after docetaxel).
Follow-up and Study End Points
All patients were followed up every 2 months regularly after the
treatment protocol was finished. Patients were evaluated and followed
up with ORR, disease control rate (DCR), progression-free survival
(PFS), median overall survival (OS), and safety profile. Responses
were assessed with the use of the Response Evaluation Criteria in
Solid Tumors (RECIST, set by an international collaboration
including the European Organisation for Research and Treatment
of Cancer, National Cancer Institute of the United States, and the
National Cancer Institute of Canada Clinical Trials Group), and toxic
effects were assessed according to the Common Toxicity Criteria of
the National Cancer Institute (Bethesda, MD) (version 2.0). Lung
tumor–related symptoms including chest pain and dyspnea before
and after CT-PFNECII were observed. CT-PFNECII–related side
effects including pain, cough, fever, hemoptysis, and pneumothorax
and chemotherapy-related side effects including myelosuppression
and gastrointestinal reaction were observed in this study.
All patients were followed up until death or until the end of the study,
with a minimum of 2 months andmaximum of 18 months of follow-up.
Statistical Analysis
All primary analyses were performed on an intention-to-treat
principle. The RECIST analysis was calculated according to the
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treatment regimens was calculated using a two-sided log-rank test.
Survival analysis was calculated according to the Kaplan-Meier
method with SPSS software (IBM, Armonk, NY). Ninety-five
percent confidence intervals (CIs) were calculated when appropriate.
Differences were considered significant at P b .05.Results
Patients
Between October 1, 2011 and July 1, 2013, a total of 34 patients
were randomly assigned to receive either CT-PFNECII combined
with second-line chemotherapy or second-line chemotherapy alone.
Among them, 17 patients received CT-PFNECII combined with
second-line chemotherapy, and 17 patients received standard second-
line chemotherapy alone. In the combination group, 7 patients
received two cycles (four times) of CT-PFNECII, and 10 patients
received one cycle (two times) of CT-PFNECII. The average cycle of
CT-PFNECII received by patients in the combination group was
1.41. Seven patients in the combination group and six patients in the
chemotherapy group had tumor-related chest pain or dyspnea. In
each group, there were five (29.41%) platinum-resistant patients
(disease recurred within 3 months to previous chemotherapy). The
overall study population had a median age of 56 years (range = 32-76
years), and baseline characteristics were generally well balanced
between the treatment groups (Table 1).Table 1. Demographics of the Patients and Their Cancers.
Characteristic CT-PFNECII +
Chemotherapy
% Chemotherapy %
(n = 17) (n = 17)
No. of Patients No. of Patients
Age, yr
Median 55 57
Range 32-74 35-76
Male sex 13 12
Weight, kg
Median 65 64
Range 41-105 38-94
Interval from last chemotherapy to inclusion, months
Median 2.5 2.5
Interquartile range 2-9 2-10
Patients with tumor-related chest pain or
dyspnea
7 6
Times of CT-PFNECII
4 7 41.18
2 10 58.82
ECOG status*
≤1 5 29.41 5 29.41
2 12 70.59 12 70.59
Cancer stage
IV 17 100 17 100
Histologic type of cancer
Adenocarcinoma 8 47.06 8 47.06
Squamous 5 29.41 7 41.18
Sarcomatoid carcinoma 1 5.88 0 0
Large cell 0 0 0 0
Other 3 17.65 2 11.77
Tumor size, cm
3-5 11 10 58.82
N5 6 7 41.18
Platinum-resistant patients 5 5 29.41
* Higher scores on the ECOG scale indicate poorer performance.Efficacy
In the combination group, 10 of 17 (58.82%) patients benefited
from our treatment in terms of disease control, and all 7 patients
(100%) who had lung tumor–related chest pain and dyspnea before
the treatment achieved significant symptom relief within 48 to 72
hours after CT-PFNECII treatment. By contrast, in the chemo-
therapy group, only 6 of 17 (35.29%) patients achieved disease
control, and 1 of 6 (16.67%) patients with tumor-related chest pain
or dyspnea acquired symptom control. Of the 17 patients in the
combination group, tumor was completely destroyed in 1 patient,
and tumors were controlled in 9 other patients with 3 patients
(17.64%) judged as partial response (PR) and 6 patients (35.29%)
judged as stable disease (SD) after two cycles of treatment. The CT
scans of two patients before and 6 months after the combination
treatment are shown in Figure 1. The ORR and DCR in the
combination group were 8 of 17 (23.53%) and 10 of 17 (58.82%),
respectively. Of the seven patients who received two cycles of CT-
PFNECII, one complete response (CR), one PR, and three SD were
achieved (ORR = 28.57%; DCR = 71.43%). And among 10
patients who received one cycle of CT-PFNECII, two PR and three
SD were achieved (ORR= 20%; DCR = 50%). ORR and DCR of
patients who received two cycles of CT-PFNECII tended to be
higher than those of patients who received one cycle of CT-
PFNECII. By comparison, 2 patients (11.76%) achieved PR, 4
patients (23.53%) achieved SD, and 11 patients (64.71%) achieved
progressive disease (PD) in chemotherapy group (ORR = 11.76%;
DCR = 35.29%).
Ranked data Ridit analysis for RECIST showed that the ORR and
DCR in the combination group were significantly higher than ORR
and DCR in the chemotherapy group, respectively (23.53% vs
11.76% for ORR, P b .01; 58.82% vs 35.29% for DCR, P b .01)
(Table 2).
The median survival time was 9.5 months in the combination
group (95% CI, 6.38-12.62 months) and 5.3 months in the
chemotherapy group (95% CI, 3.66-6.94 months). The time to
progression was 5.4 months (95% CI, 3.11-7.69 months) in the
combination group and 3.0 months (95% CI, 2.43-3.57 months) in
the chemotherapy group (Table 2). Compared with patients in the
chemotherapy group, the patients in the combination group had
significantly longer PFS (P b .01) and OS (P b .01) (Figures 2 and 3).
Safety
Adverse events associated with CT-PFNECII and chemotherapy
are summarized in Table 3. The adverse events associated with CT-
PFNECII were transient mild local pain (7 of 17 patients, 41.18%),
cough (8 of 17 patients, 47.06%), and mild pneumothorax (2 of 17
patients, 11.76%) during the procedure and mild hemoptysis (2 of 17
patients, 11.76%) for 3 to 5 days after the procedure. All the side
effects were mild and well tolerated and did not need further
medications or invasive procedures to control. Grades 3 to 5 adverse
events associated with chemotherapy were observed in four patients
(23.53%) of the combination group and in four patients (23.53%) of
the chemotherapy group. No significant difference was found
between the two groups (23.53% vs 23.53%; P N 0.05). No serious
adverse events were observed (Table 3).
Discussion
The results of our study suggest that CT-PFNECII combined with
second-line chemotherapy produced a higher response rate and
Figure 1. Comparison of two patients' CT scan before and 6 months after the combination treatment. (A) CT scan of patient A before the
treatment. This patient had progressive dyspnea before the treatment. (B) CT scan of patient A 6months after the combination treatment.
Lung tumor regressed, and symptoms were relieved 6 months after the combination treatment. (C) CT scan of patient B before the
treatment. This patient had severe chest pain. (D) CT scan of patient B 6 months after the combination treatment. Lung tumor shrank
significantly, and pain disappeared 6 months after the combination treatment.
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pretreated stage IV NSCLC. In addition, side effects of this
combination therapy were generally well tolerated.
Compared with ORR of 11.76% and DCR of 35.29% in the
chemotherapy group, the combination therapy provided an ORR
of 23.53% and a DCR of 58.82% in platinum-pretreated stage
IV NSCLC. Of note, one complete tumor regression wasTable 2. Efficacy Results.
Efficacy End Point CT-PFNECII + Chemotherapy (n = 17)
No. % 95% CI
OS,
mo
Median 9.5 7.91-10.49
PFS, mo
Median 5.4 4.30-6.70
Range 0-10
Best overall response *
CR 1
PR 3
SD 6
PD 7
ORR (CR+PR) 4 23.53
DCR (CR+PR+SD at first tumor assessment) 10 58.82
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.
n = 17 for each group.
* χ2 test.
# Ridit analysis.achieved in a patient by two cycles of combination treatment.
More importantly, all patients who had lung tumor–related chest
pain or dyspnea before our treatment achieved significant
symptom relief even within 72 hours after CT-PFNECII
treatment. Our pilot study suggests that CT-PFNECII combined
with second-line chemotherapy has potent antitumor activity
against platinum-pretreated NSCLC tumors.Chemotherapy (n = 17) P Hazard Ratio 95% CI
No. % 95% CI
5.3 3.66-6.94 .004 .29 .11-.80
3.0 2.23-3.77 .001 .26 .15-.76
0-7
.024 #
0
2
4
11
2 11.76 .000
6 35.29 .000
Figure 2. Kaplan-Meier estimates of the probability of PFS in CT-
PFNECII + chemotherapy–treated and chemotherapy-treated
patients with NSCLC. PFS of CT-PFNECII + chemotherapy–
group patients was significantly longer than that of chemotherapy
group. The P value (P = .001) was derived from a log-rank test
comparing both treatment groups. The hazard ratio of mortality
was 0.48 (95% CI, 0.44-5.35) in favor of the CT-PFNECII +
chemotherapy group.
Table 3. Side Effects in CT-PFNECII–Treated Patients.
Side Effects Patient (n = 17)
Adverse events associated with intratumoral injection All Grade 3/4
Chest pain 7 0
Cough 8 0
Pneumothorax 2 0
Hemoptysis 2 0
Adverse events associated with chemotherapy
Myelosuppression 5 2
Gastrointestinal reaction 2 2
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outcomes was also quite encouraging. Considering that 29.41% of
patients in our study population were platinum resistant (five patients
in each arm) and 58.82% of the patients (10 of 17) received CT-
PFNECII two times, the PFS of 5.4 months and OS of 9.5 months
by our combination treatment were more valuable.
The side effects of CT-PFNECII such as transient mild pain and
cough in patients with lung cancer were minimal and well tolerated
because only quite small amount of cisplatin and quite low
concentration of ethanol were injected intratumorally. In addition,
mild pneumothorax and mild hemoptysis relating to the procedure
were uncommon because we used a 22-gauge fine needle under theFigure 3. Kaplan-Meier estimates of the probability of OS in CT-
PFNECII + chemotherapy–treated and chemotherapy-treated pa-
tients with NSCLC. Survival of CT-PFNECII + chemotherapy–group
patients was significantly longer than that of chemotherapy group.
The P value (P = .004) was derived from a log-rank test comparing
both treatment groups. The hazard ratio of mortality was 0.29 (95%
CI, 0.11-0.80) in favor of the CT-PFNECII + chemotherapy group.precise guidance of CT. Furthermore, combination of CT-PFNECII
with second-line chemotherapy did not worsen common side effects
of chemotherapy. No significant differences in chemotherapy-related
adverse events in the two groups were noted, indicating clinical safety
of CT-PFNECII.
We previously found that 5% ethanol could potently inhibit
ABCG2 pump, which is a major drug transporter in protecting
platinum-resistant NSCLC cells from cytotoxic agents. We also
found that 5% ethanol-cisplatin injected intratumorally could
eradicate cisplatin-resistant lung tumors by killing chemoresistant
lung CSCs and normal lung cancer cells [10]. We speculate that the
residual unkilled but damaged tumor cells in the 5% ethanol-cisplatin
treatment group might be more fragile and sensitive to second-line
chemotherapy agents. As a result, we speculate that CT-PFNECII
treatment might have synergistic effects with systemic second-line
chemotherapies, such as docetaxel or pemetrexed, in controlling
platinum-pretreated NSCLC.
Our study showed that second-line chemotherapy pemetrexed or
docetaxel produced an ORR of 11.76% and a median survival time of
5.3 months in our patients. The ORR in our study is similar with that
in a previous report, but the median survival in our study is a little
shorter than in their study [1,11]. Possible reasons for this could be
that patients in our study were all with stage IV disease and almost
30% of them were platinum resistant, whereas only 74.8% of the
patients with NSCLC in the previous study were stage IV [1].
However, when pemetrexed or docetaxel was combined with
CT-PFNECII, the combination approach showed an ORR of
23.53% and a median survival time of 9.5 months in our
patients with platinum-pretreated NSCLC. Considering that the
ORRs were only 9.1% and 8.8% for pemetrexed and docetaxel,
respectively, in the previous study [1], these data are quite
encouraging. In addition, we found that CT-PFNECII could
efficiently control lung tumor–related chest pain or dyspnea even
within 72 hours in all patients who had these symptoms before.
This suggests that 5% ethanol-cisplatin injected intratumorally
could have potent antitumor activity against platinum-pretreated
NSCLC. Our previous studies in mouse xenografts showed that
5% ethanol could inhibit the ABCG2 pump in tumor cells as
well as drive the penetration of cisplatin into tumor cells [10,12].
Our results also support the previous findings that decreased
platinum accumulation in NSCLC tumor tissues might be an
important mechanism of platinum resistance in patients with
NSCLC [13].
Compared with a median survival of 5.2 months produced by
docetaxel and 9.4 months by selumetinib plus docetaxel in patients
with platinum-pretreated KRAS-mutant NSCLC, the median survival
of 9.5 months by our combination treatment shows promising
potential [14].
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platinum-pretreated NSCLC and 5.3 months for erlotinib in
platinum-resistant NSCLC, the median survival of 9.5 months by
our combination approach suggests that it might compare favorably
to the more expensive EGFR TKIs [7,8].
Intratumoral injection of chemotherapeutic agents in ethanol mixtures
might also be effective in treating other types of cancer. Studies by
Pietronigro and his colleagues showed that intratumoral injection of
chemotherapeutic agent bis-chloroethylnitrosourea, dissolved in 100%
ethanol could produce a 40% cure rate in rats bearing intracranial T9
tumors and 72% SD in patients with recurrent malignant glioma
[15–17]. However, our previous results showed that the chemothera-
peutic agent cisplatin, when dissolved in high concentrations of ethanol
such as 50% ethanol, produced minimal tumor inhibition [10,18].
However, the glioma tumors in patients in the Pietronigro studies were
smaller than the tumors in our patients. We speculate that smaller
tumors might be easier to be suffused by 100% ethanol, leading to
complete tumor necrosis. Further studies on the efficacy of chemother-
apy-ethanol mixtures are needed to determine the optimal therapies for
specific types of cancers.
We found that the CT-PFNECII–related side effects were mild
and well tolerated even by quite frail patients with NSCLC, and these
patients did not need further medications or invasive procedures to
control the side effects. Because a 22-gauge fine needle was used in
our CT-PFNECII administration, the procedure is essentially
“noninvasive” to the patients with NSCLC and could be safely
performed in any parts of either lung lobe under CT guidance. This is
less invasive than other procedures such as cryoablation that often
uses two cryoprobes of 15 to 17 gauges inserted percutaneously into
the lung tumor. Accordingly, the risks of pneumothorax and
hemothorax by cryoablation are more than likely higher that in our
procedure [19].
We also found in our pilot study that CT-PFNECII combined with
second-line chemotherapy might provide a higher response rate and
improved survival for patients with platinum-pretreated stage IV
NSCLC. Importantly, CT-PFNECII could efficiently control lung
tumor–related symptoms such as chest pain and dyspnea in patients
with platinum-pretreated NSCLC even within 3 days after the
procedure. Because 5% ethanol-cisplatin injected intratumorally
could regress platinum-pretreated lung tumor in NSCLC and CT-
guided percutaneous fine-needle intratumoral injection is a quite safe
clinical procedure, application of CT-PFNECII in platinum-
pretreated NSCLC warrants further study [10].
In conclusion, this study conducted in a small patient
population showed that CT-PFNECII combined with second-
line chemotherapy provides a higher response rate and improved
survival for patients with platinum-pretreated stage IV NSCLC
than second-line chemotherapy alone. As side effects of this
approach were well tolerated by the patients with cancer, its further
clinical applications in lung and other types of cancer deserves
further study in larger cohorts.References
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